Health at a glance
Current conditions, routine, and wearable trends — the context that matters first.
Active conditions
Gilbert syndrome
Hereditary. Persistently elevated bilirubin with normal liver enzymes. No treatment.
Mild scoliosis
Thoracic Cobb 9° left and lumbar Cobb 16° right. Neutral coronal and sagittal balance.
Current care
Medication
None
Supplement
Creatine · 2.5 g
Since Jun 8, 2026 · before moderate or high-intensity activity lasting more than 40 minutes.
Lifestyle
Caffeine None
Alcohol 0–1× / week
Tobacco / vaping None
Water 6+ glasses / day
Supplement calendar
Recorded dates and daily doses
Jun 8–Aug 13, 2026
Creatine Jun 8 → ongoing 2.5 g before moderate or high-intensity activity lasting more than 40 minutes.
Magnesium + B12 Jun 8–21 · 14 days One dose of each per day.
Quelat Complex Jun 22–Jul 14 · 23 days One tablet per day.
Quelat Complex
Formula per tablet
Magnesium chelate 200 mg · 36 mg elemental
Zinc chelate 7 mg elemental
Selenium chelate 50 mcg elemental
WHOOP trends
Today with 30-day context
Synced Aug 13, 2026
Recovery
72 %
30-day average 67 %
Heart rate variability
96 ms
30-day average 94 ms
Resting heart rate
39 bpm
30-day average 40 bpm
Sleep
6.5 h
30-day average 7.1 h
Clinical records
The latest results, reduced to what is useful at a glance. Original reports remain one click away.
Cardiovascular assessment · Apr 25, 2026
Cardiovascular clearance with no restrictions.
No signs of ischemia or arrhythmia. Normal blood-pressure response and preserved biventricular function.
Kynet Nordelta · Medicina Integral · Dra. Sofia Marconi (MN 162535)
LV ejection fraction 65 %
Peak capacity 9.4 METS
Measured heart rate 168 bpm
Peak blood pressure 190/60 mmHg
Measured during a cycle-ergometer test — not an absolute physiological HR max. A treadmill test may have been more representative for running.
Bloodwork over time
Laboratorio Hidalgo (2024 · 2025) · Sanatorio Las Lomas (2026) · Dr. Agote, Luis M. · Dra. Torres Patricia (2026)
In range Borderline Outside range Swipe tables horizontally →
Metabolic · Glucose
5 markers| Marker | Reference | 2024 | 2025 | 2026 | Change |
|---|---|---|---|---|---|
| Fasting glucose mg/dL | 70–99 | 82 | 80 | 84 | ↑ 5% |
| HbA1c % | 4.0–6.0 | 5.1 | 5.0 | — | ↓ 2% |
| Insulin µU/mL | 2.6–24.9 | 3.9 | — | — | — |
| Fructosamine µmol/L | 205–285 | 271 | — | — | — |
| Homocysteine µmol/L | 5–15 | — | — | 11.1 | — |
Lipid profile
8 markers| Marker | Reference | 2024 | 2025 | 2026 | Change |
|---|---|---|---|---|---|
| Total cholesterol mg/dL | < 200 | 180 | 193 | 170 | ↓ 12% |
| HDL cholesterol mg/dL | > 40 | 59 | 64 | 53 | ↓ 17% |
| LDL cholesterol mg/dL | < 100 optimal · 100–129 near optimal | 109 | 117 | 109.6 | ↓ 6% |
| Near optimal in all three tests | |||||
| Non-HDL cholesterol mg/dL | < 130 | 120 | 129 | 117 | ↓ 9% |
| Borderline in 2025 · improved in 2026 | |||||
| Triglycerides mg/dL | < 150 | 57 | 63 | 37 | ↓ 41% |
| Castelli index | < 4.5 | 3.0 | 3.0 | 3.2 | ↑ 7% |
| Apolipoprotein A1 mg/dL | 104–202 | 143 | — | — | — |
| Apolipoprotein B mg/dL | 66–144 | 80 | — | — | — |
Hematology · Red blood cells
7 markers| Marker | Reference | 2024 | 2025 | 2026 | Change |
|---|---|---|---|---|---|
| Red blood cells 10¹²/L | 4.63–6.08 | 4.87 | 4.86 | 4.66 | ↓ 4% |
| Hemoglobin g/dL | 13.7–17.5 | 15.4 | 15.8 | 15.4 | ↓ 3% |
| Hematocrit % | 40–51 | 45 | 46 | 45.4 | ↓ 1% |
| MCV fL | 79.0–92.2 | 92.6 | 94.7 | 97.4 | ↑ 3% |
| Persistently above range · consider B12/folate (B12 359, folate 9.4 — within range) | |||||
| MCH pg | 25.7–32.2 | 31.6 | 32.5 | 33.0 | ↑ 2% |
| Slightly above range | |||||
| MCHC g/dL | 32.3–36.5 | 34.1 | 34.3 | 33.9 | ↓ 1% |
| RDW % | 11.6–14.4 | 12.1 | 12.3 | 11.9 | ↓ 3% |
Hematology · White blood cells and platelets
9 markers| Marker | Reference | 2024 | 2025 | 2026 | Change |
|---|---|---|---|---|---|
| White blood cells 10⁹/L | 4.2–9.1 | 6.6 | 5.7 | 5.54 | ↓ 3% |
| Segmented neutrophils % | 34–68 | 46 | 42 | 42 | = |
| Lymphocytes % | 22–53 | 41 | 41 | 34 | ↓ 17% |
| Monocytes % | 5–12 | 10 | 13 | 7 | ↓ 46% |
| Normalized in 2026 | |||||
| Basophils % | 0–1 | 1 | 1 | 2 | ↑ 100% |
| Eosinophils % | 1–7 | 2 | 3 | 15 | ↑ 400% |
| 2026: markedly elevated · review allergy, parasites, or asthma | |||||
| Platelets 10⁹/L | 163–337 | 207 | 193 | 173 | ↓ 10% |
| ESR · 1 hour mm | 0–10 | 8 | 6 | — | ↓ 25% |
| Reticulocytes % | 0.5–1.8 | — | 1.6 | — | — |
Iron
4 markers| Marker | Reference | 2024 | 2025 | 2026 | Change |
|---|---|---|---|---|---|
| Serum iron µg/dL | 33–193 | — | 114 | 130 | ↑ 14% |
| Transferrin mg/dL | 200–360 | — | 221 | 205 | ↓ 7% |
| Transferrin saturation % | 20–55 | — | — | 52.26 | — |
| Ferritin ng/mL | 30–400 | — | 252 | 261 | ↑ 4% |
Kidney function
4 markers| Marker | Reference | 2024 | 2025 | 2026 | Change |
|---|---|---|---|---|---|
| Creatinine mg/dL | 0.67–1.17 | 0.99 | 1.17 | 1.0 | ↓ 15% |
| Upper limit · expected with greater muscle mass and high protein intake | |||||
| eGFR mL/min/1.73m² | > 90 | > 90 | > 90 | — | = |
| Urea mg/dL | 13–43 | 38 | 39 | 39 | = |
| Uric acid mg/dL | 3.4–7.0 | 6.5 | 6.53 | 5.5 | ↓ 16% |
| 2026: decreased to mid-range | |||||
Electrolytes
6 markers| Marker | Reference | 2024 | 2025 | 2026 | Change |
|---|---|---|---|---|---|
| Sodium mEq/L | 136–145 | 142 | 140 | 140 | = |
| Potassium mEq/L | 3.5–5.1 | 4.0 | 4.05 | 4.40 | ↑ 9% |
| Chloride mEq/L | 98–107 | — | 100 | 103 | ↑ 3% |
| Calcium mg/dL | 8.6–10.0 | — | 9.5 | 9.6 | ↑ 1% |
| Phosphorus mg/dL | 2.5–4.5 | — | 3.95 | 3.23 | ↓ 18% |
| Magnesium mg/dL | 1.6–2.6 | — | 2.01 | 1.8 | ↓ 10% |
Liver panel
8 markers| Marker | Reference | 2024 | 2025 | 2026 | Change |
|---|---|---|---|---|---|
| Total protein g/dL | 6.4–8.3 | 7.9 | 7.76 | 7.52 | ↓ 3% |
| Total bilirubin mg/dL | < 1.20 | 1.73 | 1.84 | 2.14 | ↑ 16% |
| Elevated in all three · Gilbert syndrome (benign) | |||||
| Direct bilirubin mg/dL | < 0.30 | 0.56 | 0.54 | 0.68 | ↑ 26% |
| Gilbert syndrome | |||||
| Indirect bilirubin mg/dL | < 0.85 | 1.18 | 1.30 | 1.46 | ↑ 12% |
| Gilbert syndrome · 2.14 − 0.68 | |||||
| ALT U/L | < 41 | 24 | 25 | 30 | ↑ 20% |
| AST U/L | < 40 | 36 | 27 | 27 | = |
| ALP · Alkaline phosphatase U/L | 40–130 | 46 | 54 | 52 | ↓ 4% |
| GGT U/L | 8–61 | — | 21 | — | — |
Muscle enzymes
3 markers| Marker | Reference | 2024 | 2025 | 2026 | Change |
|---|---|---|---|---|---|
| CK U/L | 39–308 | — | 177 | 92 | ↓ 48% |
| Consistent with strength training | |||||
| LDH U/L | 125–220 | — | — | 183 | — |
| Amylase U/L | 28–100 | — | 73 | — | — |
Thyroid
7 markers| Marker | Reference | 2024 | 2025 | 2026 | Change |
|---|---|---|---|---|---|
| TSH µUI/mL | 0.27–4.20 | 2.99 | 2.97 | 1.13 | ↓ 62% |
| Free T4 ng/dL | 0.93–1.70 | 1.38 | 1.37 | — | ↓ 0.7% |
| Total T3 ng/mL | 0.80–2.00 | 1.15 | 1.16 | 0.91 | ↓ 22% |
| 2026: 90.9 ng/dL converted to ng/mL | |||||
| Total T4 µg/dL | 4.6–12.0 | 7.8 | — | 8.5 | ↑ 9% |
| TSH receptor antibodies UI/L | < 1.75 | < 1.10 | — | — | — |
| Anti-thyroglobulin antibodies UI/mL | < 115.0 | 19.0 | — | — | — |
| Thyroid peroxidase antibodies UI/mL | < 34.0 | < 15.0 | — | — | — |
Sex hormones
4 markers| Marker | Reference | 2024 | 2025 | 2026 | Change |
|---|---|---|---|---|---|
| Total testosterone ng/mL | 2.49–8.36 | 6.92 | — | 7.75 | ↑ 12% |
| Free testosterone pg/mL | 66.00–174.00 | 127.50 | — | 126.6 | ↓ 0.7% |
| 2026: 0.439 nmol/L converted to pg/mL | |||||
| Bioavailable testosterone ng/mL | 1.50–4.00 | 2.93 | — | 2.91 | ↓ 0.7% |
| 2026: 10.09 nmol/L converted to ng/mL | |||||
| SHBG nmol/L | 13.5–71.4 | — | — | 55.0 | — |
Vitamins
4 markers| Marker | Reference | 2024 | 2025 | 2026 | Change |
|---|---|---|---|---|---|
| Vitamin D · 25(OH) ng/mL | 30–100 sufficient | 24.6 | 43.9 | 59.5 | ↑ 36% |
| Increased from insufficient (24.6) to sufficient (59.5) | |||||
| Vitamin B12 pg/mL | 187–883 | — | — | 359 | — |
| Folate ng/mL | 3.1–20.5 | — | — | 9.4 | — |
| Vitamin A · retinol mg/L | 0.24–0.95 | — | — | 0.57 | — |
Serum protein electrophoresis
6 markers| Marker | Reference | 2024 | 2025 | 2026 | Change |
|---|---|---|---|---|---|
| Albumin g/dL | 3.39–4.63 | 4.89 | 4.71 | 4.3 | ↓ 9% |
| 2026: within range | |||||
| Alpha-1 globulins g/dL | 0.18–0.44 | 0.24 | 0.23 | 0.14 | ↓ 39% |
| 2026: slightly low · inter-laboratory variation | |||||
| Alpha-2 globulins g/dL | 0.50–0.95 | 0.62 | 0.63 | 0.74 | ↑ 17% |
| Beta-1 globulins g/dL | 0.32–0.56 | 0.39 | 0.40 | 0.59 | ↑ 47% |
| 2026: slightly above range | |||||
| Beta-2 globulins g/dL | 0.20–0.46 | 0.37 | 0.37 | 0.33 | ↓ 11% |
| Gamma globulins g/dL | 0.61–1.66 | 1.39 | 1.41 | 1.40 | ↓ 0.7% |
Serology · 2024 only
7 markers| Marker | Reference | 2024 | 2025 | 2026 | Change |
|---|---|---|---|---|---|
| VDRL | Non-reactive | Non-reactive | — | — | — |
| HBsAg · Hepatitis B | Non-reactive | Non-reactive | — | — | — |
| HIV 1/2 + p24 antigen | Non-reactive | Non-reactive | — | — | — |
| Herpes simplex 1 IgG | Negative | Negative | — | — | — |
| Herpes simplex 1 IgM | Negative | Negative | — | — | — |
| Herpes simplex 2 IgG | Negative | Negative | — | — | — |
| Herpes simplex 2 IgM | Negative | Negative | — | — | — |
Urinalysis
6 markers| Marker | Reference | 2024 | 2025 | 2026 | Change |
|---|---|---|---|---|---|
| pH | 5–8 | 6.0 | 6.0 | — | = |
| Specific gravity | 1.003–1.035 | 1.022 | 1.017 | — | ↓ 0.5% |
| Protein | Negative | Negative | Negative | — | — |
| Glucose | Negative | Negative | Negative | — | — |
| Bilirubin | Negative | Negative | Negative | — | — |
| Ketones | Negative | Negative | Negative | — | — |
Structure and movement
Stable structural findings and the footwear currently in use.
Mild scoliosis
Spine radiograph · May 2023
Thoracic Cobb9° left
Lumbar Cobb16° right
Pelvic tilt10 mm
BalanceNeutral
Foot profile
SizeUS 10 / 10.5 · wide
PatternSupination · outer-edge loading
Hallux valgus tendency. Uses toe spacers daily. Minimal footwear for walking and casual use since Dec 2025; not for running or tennis.
Xero
Daily · casual · walking
Zero-drop · wide toe box · flexible sole
Altra Torin 8
Current running shoe
Zero-drop · cushioned · wide toe box
History
Resolved issues, known family history, and source documents.
Resolved
Right lateral / peroneal leg pain
Previously appeared on runs longer than 8–10 km. Resolved with consistent running and strength work.
Family history
Grandfather
Myocardial infarction
Smoker